BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CRLX101: Interim Phase IIa data

Interim data from 20 evaluable patients with non-small cell lung cancer (NSCLC) in the Phase IIa portion of an ongoing, open-label, U.S. Phase I/IIa trial showed that 15 mg/m 2 CRLX101 every other week produced 14 cases of stable disease for >=3 months and 4...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >